Tuberculosis Preventive Therapy for People Living with HIV in Mozambique: Eligibility, Completion, Coverage and TB Disease Rates, April 2021 to March 2024

IntroductionTuberculosis (TB) is one of the main causes of morbidity and mortality worldwide, especially in people living with HIV (PLHIV). TB preventive treatment (TPT) reduces the incidence and mortality of TB in PLHIV. As of March 2021, in Mozambique, only 40% (182,512/460,080) of those eligible had received a full course of TPT. The aim of this study is to describe the variation in TPT provision and the TB incidence in PLHIV in Mozambique from April 2021 to March 2023. MethodologyWe analyzed provincial reports with monthly and semi-annual aggregated data of TPT and TB Monitoring, Evaluation, and Report (MER) indicators of 591 Health Facilities supported by The U.S. Presidential Emergency Plan for Aids Relief (PEPFAR) at the national level. The analyses included the four following indicators: TPT eligibility, TPT completion, TPT coverage, and TB disease incidence rate. TPT data were analyzed using a MS Excel 365 database. Data were collected periodically and analyzed using tables and graphs with variation lines. ResultsTPT eligibility decreased by 75%, from 687,711 in April 2021 to 170,011 in March 2024. TPT coverage increased from 42% (489,905/1,177,616) in April 2021 to 89% (1,405,139/1,575,150) in March 2024. TPT completion rate also increased by 8%, from 81% (120,692/148,507) to 89% (104,690/117,764). TPT coverage increased by 47%, from 41% (489.905/1.177.616) in April 2021 to 89% (1.405.139/1.575.150) in March 2024. TB disease incidence rate among PLHIV decreased by 0,15%, from 0.65% (7,801/1,208,559) to 0.5% (7,974/1,592,102). ConclusionIn 3 years, Mozambique drastically increased the number of PLHIV who had received TPT, with almost 90% TPT coverage achieved among PLHIV through a system-wide multidisciplinary approach.